AMGN vs TMO
AMGN: Amgen is a leading biotechnology firm dedicated to developing innovative human therapeutics to address critical unmet needs in areas like oncology, inflammation, and cardiovascular disease. TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
Side-by-side fundamentals
| Metric | AMGN | TMO | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $443.84 | $628.74 | |
| Market cap as of 2026-08-24 | $240.0B | $232.5B | |
| P/E as of 2026-08-24 | 27.56 | 33.85 | AMGN lower |
| PEG as of 2026-08-24 | 5.48 | 3.39 | TMO lower |
| Net margin as of 2026-08-24 | +22.9% | +15.0% | AMGN higher |
| Gross margin as of 2026-08-24 | +74.3% | +40.9% | AMGN higher |
| Operating margin as of 2026-08-24 | +30.3% | +17.6% | AMGN higher |
| ROE as of 2026-08-24 | +89.3% | +13.3% | AMGN higher |
| ROA as of 2026-08-24 | +9.5% | +6.3% | AMGN higher |
| Debt / equity as of 2026-08-24 | 4.90 | 0.81 | TMO lower |
| Revenue growth (YoY) as of 2026-08-24 | +9.1% | +7.2% | AMGN higher |
| Revenue CAGR (3y) SEC XBRL | +11.8% | -0.3% | AMGN higher |
| Dividend yield as of 2026-08-24 | +3.2% | +0.3% | AMGN higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-24 | 0.42 | 0.76 | |
| 1-year return as of 2026-08-24 close | +51.1% | +25.8% | AMGN higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.